Post on 07-May-2015
Laparoscopy for Gastric Cancer
Abeezar I. Sarela MBBS FRCS
Consultant in Upper Gastrointestinal & Minimally Invasive Surgery
The General Infirmary at Leeds, United Kingdom
Massachusetts General Hospital, August 17, 2006
Laparoscopy for Gastric Cancer
The General Infirmary at Leeds
Laparoscopy for Gastric Cancer
Chairs of Surgery in LeedsBerkeley G.A. Moynihan FRCS
• Pioneer abdominal surgeon
• Founder: Association of Surgeons of GB
• Founder: The British Journal of Surgery
Laparoscopy for Gastric Cancer
Chairs of Surgery in LeedsPhillip Allison FRCS
Laparoscopy for Gastric Cancer
Chairs of Surgery in LeedsJohn C. Goligher FRCS
•Eminent colorectal surgeon•Peptic ulcer surgery
Laparoscopy for Gastric Cancer
Chairs of Surgery in LeedsContemporary
• David Johnson FRCSPioneer of HSV and bariatric surgery
• Pierre J. Guillou FRCSPI: MRC CLASICC Trial
• Michael J. McMahon FRCSPresident, Association of
Laparoscopic Surgeons of GB
Laparoscopy for Gastric Cancer
Upper GI & Laparoscopic SurgeryCurrent Unit in Leeds
• Simon P. Dexter FRCS
• Michael J. McMahon FRCS
• Abeezar I. Sarela FRCS
• Henry M. Sue-Ling FRCS
Laparoscopy for Gastric Cancer
Gastric CancerRole of Laparoscopy
• Staging– for carcinoma
• Curative Resection– for carcinoma and GIST
• Palliation• Treatment of sequels of open gastrectomy
– Incisional hernia– Intestinal obstruction
Laparoscopy for Gastric Cancer
Staging Philosophy
• CT staging: False-negative results
• M1 is incurable disease
• Treatment-intent
– Optimise quality of life
– Prolong length of survival
– Minimise treatment-related complications
Laparoscopy for Gastric Cancer
Laparoscopic Staging of Gastric CarcinomaMemorial Sloan Kettering Cancer Center Experience
• Period: 1993-2002
• Gastric or GOJ carcinoma 1748 patients
• Selection criteria:– Clinically & radiologically M0– Acceptable risk for major operation– No obstruction or bleeding
• Laparoscopy 657 patients
• Laparoscopic M1 23%• Laparoscopic false-negative M0 9%
Sarela AI (Brennan MF) et al. Am J Surg. 2006;191:134-38
Laparoscopy for Gastric Cancer
Laparoscopic Staging
For patients with laparoscopic M1 disease, is no resection of the primary
tumour associated with:
•High incidence of complications?
•Shorter survival?
Laparoscopy for Gastric Cancer
C u ra t iv e -in te n tE x c lu d e d
L a p a ro s c o p yo n ly
N = 1 4 7
M 1
M 1N = 1 8
T 4 tu m o u rN o M 1
E x c lu d e d
L a p a ro to m yN o re s e c t io n
M 0
S ta g in g L a p a ro s c o p yN = 7 1 8
P ro s p e c t iv e ly m a in ta in e d d a ta b a s e1 9 9 2 -2 0 0 2
N = 1 7 4 8
Sarela AI (Brennan MF) et al. Ann Surg 2006;243:189-95
Laparoscopic M1Gastric Carcinoma, No ResectionMemorial Sloan Kettering Cancer Center Experience
Laparoscopy for Gastric Cancer
Laparoscopic M1, No resection
18%
16%
27%
23%
16%
Entire
Proximal
GEJ
Body
Antrum
165Patients
Sarela AI (Brennan MF) et al. Ann Surg 2006;243:189-95
Primary Tumour Location
Laparoscopy for Gastric Cancer
Laparoscopic M1, No Resection
30%
35%
8%16%
10%
P3
P2
P1Combined
Liver
Peritoneal metastasisP1: adjacent to stomachP2: few distant lesionsP3: disseminated
165 patients
9%
Laparoscopy for Gastric Cancer
Laparoscopic M1, No Resection
O b s tru c t io n3 2 p a t ie n ts
B le e d in g 8 p a t ie n ts
P e r fo ra t io n 1 p a t ie n t
In te rv e n t io n o n p r im a ry tu m o r4 1 (4 2 % ) p a t ie n ts
G a s tr ic A d e n o c a rc in o m aL a p a ro s c o p ic s ta g e M 1
N o g a s t r e c to m y9 7 p a t ie n ts
Sarela AI (Brennan MF) et al. Ann Surg 2006;243:189-95
Intervention
Laparoscopy for Gastric Cancer
Laparoscopic M1, No Resection
• Intervention 42%
• Laparotomy 8%
• Mortality 1%
Sarela AI (Brennan MF) et al. Ann Surg 2006;243:189-95
Laparoscopy for Gastric Cancer
Laparoscopic M1, No ResectionSurvival
Months
42363024181260
Survival
1.0
.8
.6
.4
.2
0.0
Median survival: 10 monthsOne year survival: 39%
156 patients
Laparoscopy for Gastric Cancer
M1 Gastric CancerLeeds Experience
• Total : 211 patients (2001-2004)• M1 disease: 67 patients• Intervention
– Obstruction: 20%– Bleeding : 7%– Perforation: 1%
• Laparotomy: 9%• Median Survival: 7 months
Sarela A et al. Arch Surg. In press
Laparoscopy for Gastric Cancer
Laparoscopic M1 Gastric Carcinoma
• Unique group– Minimally symptomatic disease– Satisfactory functional performance status
• No-resection is safe and does not appear to shorten survival– Quality of life?
• Role for resection of M1 disease?
Laparoscopy for Gastric Cancer
Laparoscopic Gastric Resection
GIST
Carcinoma
Laparoscopy for Gastric Cancer
Laparoscopic Gastric ResectionGIST
• Extra-luminal or Exophytic tumors– “Closed” wedge-excision
• Intra-luminal or Endophytic tumors– “Open” wedge-excision
• Segmental gastrectomy and anastomosis
Laparoscopy for Gastric Cancer
Laparoscopic Gastric Resection for CarcinomaAims
• Entirely laparoscopic
• Specimen-retrieval via lower abdominal incision
• Negative primary tumor resection-margins
• D2 lymphadenectomy
Laparoscopy for Gastric Cancer
Laparoscopic Gastric Resection for CarcinomaOutcome Measures
• Feasibility• Safety• Peri-operative benefits• Longer-term “mechanical” benefits
– Incisional hernia– Intestinal obstruction
• Recurrence • Survival
Laparoscopy for Gastric Cancer
Laparoscopic Gastrectomy for Carcinoma2005-2006
• Selected group: 11 patients
• 8 men, 3 women
• Pre-operative stage– Early gastric cancer: 6 patients– Advanced gastric cancer: 5 patients
• Selection bias for advanced cancer patients– Pulmonary disease
Laparoscopy for Gastric Cancer
• Subtotal: 7 patients, Total: 4 patients
• Conversion: 2 patients
• Major post-op complication: 3 patients
• Hospital stay: median 15 days (7-48)
• Lymph node retrieval: median 22 (10-40)
• Positive resection margins: 3 patients
Laparoscopic Gastrectomy2005-2006
Laparoscopy for Gastric Cancer
Laparoscopic GastrectomyComplications
Operation Complications Treatment
1. Lap. Total G Duodenal leak
Bleeding
Re-laparoscopy
Embolisation
2. Lap. Total G Bleeding
O-J leak
Re-laparoscopy
Chest drain
3. Lap Subtotal G (C)
Abscess CT-drain
Laparoscopy for Gastric Cancer
Laparoscopic Gastrectomy for Carcinoma
• Entirely laparoscopic approach is feasible
• Steep learning curve
• Safe (?)
• Tactile loss for primary tumour extent
• Lymph node yield > minimum of 15 (AJCC)
• Patient-selection?